End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
815 INR | +8.59% | +1.53% | +24.03% |
Apr. 25 | Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Glenmark Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Sales 2024 | 22.83B 274M | Sales 2025 * | 25.79B 309M | Capitalization | 99.85B 1.2B |
---|---|---|---|---|---|
Net income 2024 | 4.71B 56.46M | Net income 2025 * | 5.5B 65.99M | EV / Sales 2024 | 4.17 x |
Net cash position 2024 * | 3.5B 41.94M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.87 x |
P/E ratio 2024 |
20.2
x | P/E ratio 2025 * |
18.2
x | Employees | 1,824 |
Yield 2024 * |
2.59% | Yield 2025 * |
2.95% | Free-Float | 15.72% |
Latest transcript on Glenmark Life Sciences Limited
1 day | +8.59% | ||
1 week | +1.53% | ||
Current month | +4.93% | ||
1 month | +4.93% | ||
3 months | -2.54% | ||
6 months | +30.23% | ||
Current year | +24.03% |
Managers | Title | Age | Since |
---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 19-08-12 |
Director of Finance/CFO | - | 22-05-31 | |
Compliance Officer | - | 21-02-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Manju Agarwal
BRD | Director/Board Member | 66 | 20-10-29 |
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 19-08-12 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 18-10-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 815 | +8.59% | 584,264 |
24-04-25 | 750.5 | -9.20% | 589,960 |
24-04-24 | 826.5 | +0.03% | 24,936 |
24-04-23 | 826.2 | -1.58% | 88,182 |
24-04-22 | 839.6 | +4.60% | 109,398 |
End-of-day quote NSE India S.E., April 25, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.03% | 1.2B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- GLS Stock